Intelligent Health, Safety and Security Solutions

T-Mobile shares our commitment to improving public health so that we can safely get back to the life we once knew.

BOSTON (PRWEB)
November 15, 2021

Vizsafe, Inc. today announced it has selected T-Mobile as the preferred wireless provider to connect its Health Screening and Health Pass Verification solutions over the nation’s largest, fastest and most reliable 5G network. Vizsafe has also joined the T-Mobile for Business Partner Program to provide their health, safety and security solutions to enterprise customers.

As COVID-19 and new variants continue to strain the public health system, economic infrastructure, and our way of life, innovative solutions are needed that can address both the immediate and long-term impact of this pandemic, as well as other infectious diseases. Throughout this crisis, Vizsafe has been delivering the most advanced capabilities available on the market to help organizations of all sizes protect the safety of their employees and visitors while reducing health risks, processing more than 5 million transactions per month.

Vizsafe’s patented Geoaware® Access products and services are proudly Made in the USA, offering a wide range of flexible options, including:

• 
  Touchless Health Screening & Health Pass Verification Kiosks – Verifies identity credentials, scans SMART® Health Cards and measures vital signs using AI powered medical grade sensors.
• Health Pass Verification Tablets – Validates testing, vaccination credentials and SMART® Health Cards for intelligent access control.
• Self-Attestation/Symptom Checker Apps – Provides configurable health self-attestation/symptom checker forms with QR codes using web and mobile apps.
• Incident Management Dashboards & Analytics – Uses real-time web dashboards for insights, analytics and compliance reporting.

“The pursuit of health, safety and security deserves 4G LTE that covers 99% of people across the country for today and the largest, fastest and most reliable 5G network for wireless connectivity to power future innovation, which is why we didn’t look any further than T-Mobile,” said Peter Mottur, President and CEO of Vizsafe. “T-Mobile shares our commitment to improving public health so that we can safely get back to the life we once knew.”

About Vizsafe

Vizsafe, Inc. is a leading provider of health, safety and security solutions, delivering its patented Geoaware® intelligence dashboard with location-powered mobile apps, touchless AI-driven health screening, real-time communications and incident manangement. Vizsafe’s innovative technologies are proudly Made in the USA and are enabling smarter and more responsive communities globally. Their platform is HIPAA compliant and has been awarded SAFETY Act Designation as a Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security, supporting the most demanding safety, security and risk management applications.

For more information, please visit: https://www.vizsafe.com

SMART(TM) and the SMART logo is a trademark of The Children’s Medical Center Corporation. Used with permission.

Share article on social media or email:

Regardless of the etiology of the muscle disease, the measurable changes that can be seen through imaging have a great deal of commonality — there is often inflammation, fatty infiltration, muscle atrophy and fibrosis.

TORONTO (PRWEB)
November 15, 2021

Neuromuscular disorders affect the neuromuscular system and affect the nerves that control the muscles, the muscles themselves and the interface between the nerves and the muscles. These disorders include amyotrophic lateral sclerosis (ALS), muscular dystrophy, myositis, spinal muscular atrophy, amongst others. Many of these diseases are genetic, such as duchenne muscular dystrophy, while others, such as sporadic inclusion body myositis (sIBM) are idiopathic autoimmune inflammatory myopathies.

There are currently no cures for any of these diseases. Regardless of the etiology of the muscle disease, the measurable changes that can be seen through imaging have a great deal of commonality — there is often inflammation, fatty infiltration, muscle atrophy and fibrosis. Many of these characteristics can be quantified through imaging, and this webinar will discuss how to apply different imaging techniques to make these measurements in the context of a clinical trial.

Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, Philips BioTel Research in a live webinar on Tuesday, December 7, 2021 at 1pm EST to learn about the importance of choosing the right imaging modality for clinical trials of neuromuscular disorders.

For more information, or to register for this event, visit Imaging for Neuromuscular Disorders in Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

This presentation will focus specifically on applications related to the use of specific-pathogen free and germ-free mice as preclinical models.

TORONTO (PRWEB)
November 15, 2021

Even if the causality is not always established, a microbial imbalance or dysbiosis are being increasingly linked to several diseases, including gastrointestinal and dermal diseases, metabolic disorders, CNS pathologies and cancer. Furthermore, the microbiome has been shown to influence the efficacy of immunotherapy and chemotherapeutic agents and the metabolism of drugs. Based on preclinical and clinical studies, different strategies (e.g., fecal material, defined consortium, single strain) are adopted to modulate the composition of the microbiome and exploit its immunogenicity to treat diseases in first line treatment or to circumvent primary resistance to standard of care.

Owing to their scientific and technological expertise, Oncodesign and Taconic propose tailor-made strategies to clients for investigating the safety/efficacy of their microbiome-based therapeutics. This presentation will focus specifically on applications related to the use of specific-pathogen free and germ-free mice as preclinical models.

It will be a unique opportunity to interactively discuss, debate and have questions answered about how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.

Join Sylvie Maubant, Head of Study & Research Unit – In Vivo Sciences Department, Oncodesign; and Ivan Gladwyn-Ng, Field Application Scientist, Taconic in a live webinar on Tuesday, December 7, 2021 at 11am EST (4pm GMT/UK) to gain deeper insight into preclinical models for evaluating microbiome products.

For more information, or to register for this event, visit Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

MIAMI BEACH, Fla. (PRWEB)
November 15, 2021

The founders of Pasithea Therapeutics, a new biotech company built to develop new treatments for mental health issues, recently spoke on entrepreneurship in science. The company was founded by Stanford University’s Professor Lawrence Steinman, now Executive Director, and Dr. Tiago Reis Marques, current CEO formerly of King’s College of London. Pasithea operates in-clinic in the UK, where research helmed by Marques is constantly being conducted to develop new treatments.

“In building a new company we wanted to do research and drug development, but also knew that an on-the-ground infrastructure was critical to both our work and our business,” said Steinman. “We’re thrilled to be working with I.V. Doc® in the US and Zen Healthcare in the UK to help our company earn profitability quicker than it would have otherwise.”

As the world continues to be shaken by the COVID-19 pandemic and the number of people suffering from mental health issues rises worldwide, Pasithea aims to provide relief to those in need. The biotech company reports that the size of the depression and anxiety treatment markets is expected to rise to $19.2 billion in 2027, and that mental disorders will lead to a $16 trillion loss to the global economy between 2010 and 2030.

Marques added, “I am happy to be working with partners to gain on-the-ground experience in treating mental health, as it will offer invaluable insight into my research. I truly think this strategy is best not just for our profitability, but will ultimately allow me and my team to produce the best research possible.”

On September 15th, the company became tradable on the Nasdaq Capital Market under the symbol “KTTA”, with warrants available as “KTTAW.” 4,800,000 units of this stock were made available at $5.00 each, after the company raised approximately $24.0 million on the public market.

About Pasithea Therapeutics:

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

The company will also be working by providing on-the-ground treatments to help better understand and meet the needs of patients. Through clinics in the United Kingdom and at-home services in the United States, Pasithea will gain deeper knowledge on the effects of Ketamine IVs to treat depression. This innovative new practice is still currently being researched within the medical field, but has shown great promise in preliminary studies.

Share article on social media or email:

“Thanks to our generous partners, Holiday Meals for Military® allows us to provide much-needed support to military families so they can enjoy the holidays and a “thank you” from the communities they’ve worked so hard to protect.” – Brig Gen (ret) John I Pray Jr, Operation Homefront President and CEO

SAN ANTONIO (PRWEB)
November 15, 2021

Operation Homefront’s Holiday Meals for Military program has launched with the goal of putting meals on the tables of more than 15,000 American military families by December 17, 2021. The program, which is in its 12th year, provides junior- and mid-grade enlisted military families with all the grocery items necessary to prepare a traditional holiday meal, helping to ease their financial hardships and to make the holiday season brighter for those who sacrifice so much on behalf of all Americans. The national nonprofit expects to achieve a key milestone this holiday season of serving its 550,000th military family member since the program officially began in 2010.

Thanks to the generous support of partners including Chobani, P&G, Grunt Style Foundation, Lockheed Martin, Food Lion, Bob Hope Legacy, San Antonio Shoemakers (SAS), and others, meals are being distributed at more than 80 events across the country this holiday season, starting with Fairchild, Washington and ending at Travis Air Force Base, California. This valuable program connects civilians to military families helping them start strong and stay strong this holiday season and beyond.

“Military families are often far from their loved ones during the holiday season, making it difficult for them to enjoy the traditions many Americans look forward to,” said Brig. Gen. (ret.) John I. Pray Jr., President and CEO of Operation Homefront. “Thanks to the unwavering support of our many generous partners, our highly-regarded Holiday Meals for Military® program allows us to provide much-needed support to our military families so they can enjoy the holidays and a tangible “thank you” from the communities they have worked so hard to protect.”

Chobani is a pivotal partner of Operation Homefront and its programs, including Holiday Meals for Military. Chobani is dedicated to making high-quality and nutritious food accessible to more people, while elevating its communities and making the world a healthier place.

“As a proud American company, Chobani is honored to partner with Operation Homefront,” said Peter McGuinness, Chobani President and Chief Operating Officer. “Since 2018, Chobani has donated more than $2.25 million through our charity product, Hero Batch. This is a special red, white and blue yogurt we designed specifically to shine a spotlight on the U.S. military in stores all across the country and to raise money and support for military families in need all year long.”

In addition, Chobani allocated donations to help military families directly impacted by the COVID-19 pandemic in California and Texas.

Procter & Gamble (P&G) joins Operation Homefront for the 6th year to provide an assortment of useful household and personal care items for the families attending our distribution events across the country. This ties to the Start Strong Stay Strong initiative launched with P&G earlier this year to brighten the lives of those that serve our nation and their families.

“P&G has been committed to supporting the military community for over 150 years and we are proud to partner with Operation Homefront,” said Marc Knowles, Global Military Team Leader at Procter & Gamble. “Through our partnership, we have seen how their programs impact the lives of our nation’s military families and together, we are steadfast in our commitment to help these families start strong in their communities and stay strong throughout their journeys.”

For the 5th year in a row, thanks to a donation from Bob Hope Legacy, any military families on the waitlist will be moved up to ensure they also receive a meal. Bob and Dolores Hope’s enduring wish to take care of the military and their families lives on through this impactful contribution.

Registration is now open for eligible military families to receive holiday meals nationwide, including events in Dallas-Fort Worth, TX, Tampa, FL, Washington D.C., San Diego, CA, and Norfolk, VA. The annual program will conclude on December 17. To see all Holiday Meals for Military® event locations and to register, visit OperationHomefront.org/holiday-meals-for-military.

In addition to distributing meals in November and December, Operation Homefront holds Holiday Meals for Military events throughout the year for Easter, Independence Day, Veterans Day, and more.

The Holiday Meals for Military program was born from a chance encounter in a supermarket in Utica, New York near Fort Drum. A soldier, his wife, and infant were in line with a handful of grocery items for their Thanksgiving meal. At the register, the family realized they were short money and began to remove items from their cart. A Beam Suntory executive was in line behind them, and he paid the $12 total for their groceries. In talking to the family, the executive learned the soldier had just returned from deployment and was having trouble providing for his family due to some unexpected expenses.

From that chance meeting, Holiday Meals for Military was born. A pilot program was launched to distribute 500 holiday meal kits to military families. Since 2010, the program has grown every year. The growth is due to the generous support of many sponsors who provide funding, food items, venues, storage, shipping and valuable volunteer hours.

This year’s Holiday Meals for Military® program will comply with all federal, state, and local COVID-19 guidelines and deliver meals in a safe, socially distant drive-through format. Meals will be distributed as traditional meal kits or in the form of a gift card, giving families the opportunity to purchase their own holiday meal contents.

For more information on how to volunteer or donate, visit OperationHomefront.org/holiday-meals-for-military.

#     #     #

About Operation Homefront

Founded in 2002, Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military families so that they can thrive – not simply struggle to get by – in the communities they have worked so hard to protect. Recognized for superior performance by leading independent charity oversight groups, 90 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America’s military families. For more information, visit OperationHomefront.org.

About Start Strong, Stay Strong

Operation Homefront launched ‘Start Strong, Stay Strong,’ a national brand campaign in March 2021. The initiative brings much-needed attention to the dedicated service of our military families and the support that Americans can provide to build the stability, connections and comfort these families deserve to start strong in their communities and stay strong throughout their journeys. #StartStrongStayStrong. Find out more at operationhomefront.org/startstrongstaystrong.

There are a lot of theoretical discussions and multiple approaches to conducting DCTs, but it’s most useful to see how they are implemented from a real operational perspective.

TORONTO (PRWEB)
November 15, 2021

Running decentralized clinical trials (DCTs) is a new and complex challenge for most stakeholders within the pharmaceutical industry. There are a lot of theoretical discussions and multiple approaches to conducting DCTs, but it’s most useful to see how they are implemented from a real operational perspective. What is the impact on the patients? What is their perspective? Is it possible to create a simple, effective, and feasible approach to DCTs?

This webinar Decentralized Clinical Trials: Implementation of a Hybrid Model from a Site and Sponsor Perspective will focus on discussing the flexible tools necessary for adapting work to a number of different clinical trial models, including site-based, hybrid and virtual trials.

The speakers will answer the key questions during the speech, e.g.:

• 
      What are the challenges of DCTs for sites and sponsors?
•     What are the new roles for sites and PIs (e.g., patient oversight, assistance, and home visits)?
•     How can staff better meet the needs of patients through DCTs (e.g., improving access to trials, patient journey and retention)?
•     How will DCTs change the collaboration between sponsors, PIs and sites?

All participants, who register for this webinar will learn how to solve some of the most common challenges of running DCTs to ensure the needs of patients, sites and sponsors are met.

They will take part in the webinar: Dr. Ole Dammann, CEO, kfgn I Site Operations & Services, and Board Member, Country Head Germany, Pratia S.A.; Karl-Ludwig Radek, Internal Project Lead for IMI TRials@Home, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Michał Kwiatek, MD, PhD, Investigator, Site Director, Pratia S.A.

Live webinar is being organized on Thursday, December 2, 2021 at 10am EST (3pm GMT/UK).

More information and register for this event on page: Decentralized Clinical Trials: Implementation of a Hybrid Model from a Site and Sponsor Perspective.

ABOUT PRATIA

Pratia is a platform for innovative medicine which offers the best mix of sites, expertise and access to patients for each protocol, as well as close collaboration with the local healthcare systems. We are a research organization platform that brings tech-savvy, adaptable solutions for innovative treatments at your convenience. With 90+ centers across 6 countries in Europe, and 700+ Clinical Trials carried out since 2012, we strive to connect patients & professionals via our platform in order to create better access to innovative care. We can conduct studies within 30+ therapeutical areas at the convenience of our Patients, Partners, and Physicians. We can address the dynamically changing requirements in the industry, including remote monitoring and decentralized studies.

More about Pratia: https://pratia.com/

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

More about Xtalks: http://xtalks.com

Information about hosting a webinar: http://xtalks.com/why-host-a-webinar/

Share article on social media or email: